Intercept to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information
May 26, 2021 16:30 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 06, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter Company narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million...
Intercept to Announce First Quarter 2021 Financial Results on May 6, 2021
April 26, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Announces Departure of Chief Financial Officer
March 10, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Rocco Venezia Appointed Chief Accounting Officer and Acting CFO -Intercept Reiterates 2021 Financial Guidance - NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc....
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update
February 25, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year Intercept provides initial 2021...
Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors
February 23, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present at Upcoming Investor Conferences
February 19, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints Linda Richardson as Chief Commercial Officer
February 17, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept’s Executive Leadership Team NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intercept...